VEGF-A NanoAb - Scinai Immunotherapeutics/The Max Planck Society/University Medical Center Gottingen
Latest Information Update: 03 Nov 2023
At a glance
- Originator The Max Planck Society; University Medical Center Gottingen
- Developer Scinai Immunotherapeutics
- Class Eye disorder therapies; Single-domain antibodies
- Mechanism of Action Vascular endothelial growth factor A modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Wet age-related macular degeneration
Most Recent Events
- 12 Sep 2023 Early research in Wet age-related macular degeneration in Germany (Parenteral) prior to September 2023 (Scinai Immunotherapeutics pipeline, September 2023)